Get the Stockscreener App
0.0623
23.37%
0.0118
Pre-market:
.06
-0.0023
-3.69%
Cero Therapeutics Holdings Inc stock is traded at $0.0623, with a volume of 43.04M.
It is up +23.37% in the last 24 hours and down -71.44% over the past month.
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
See More
Previous Close:
$0.0505
Open:
$0.0532
24h Volume:
43.04M
Relative Volume:
0.62
Market Cap:
$9.36M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.96%
1M Performance:
-71.44%
6M Performance:
-82.32%
1Y Performance:
+0.00%
1-Day Range:
$0.0527
$0.065
1-Week Range:
$0.048
$0.087
52-Week Range:
$0.0467
$10.95
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Name
Cero Therapeutics Holdings Inc
Sector
Industry
Phone
650-407-2376
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare CERO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
0.0623 | 9.36M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.18 | 105.12B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.51B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.99 | 37.67B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 31.37B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.13 | 27.36B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cero Therapeutics Holdings Inc Stock (CERO) Latest News
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Cero Therapeutics holdings sees $400,456 in stock sales by YK Bioventures - Investing.com Australia
Cero Therapeutics sees $383,369 in stock sales by YK Bioventures - Investing.com
CERo Therapeutics appoints Chris Ehrlich CEO - MSN
CERo Therapeutics Holdings, Inc. Appoints Chris Ehrlich CEO - Marketscreener.com
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewswire
CERo Therapeutics Names Chris Ehrlich Permanent CEO, Advances Novel Cancer Treatment Pipeline - StockTitan
Cero therapeutics investor Sloan Stuart sells $55,538 in stock By Investing.com - Investing.com India
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.70% - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
United States shares lower at close of trade; Dow Jones Industrial Average down 0.70% - MSN
CERo Therapeutics Holdings Inc. (CERO) reports earnings - Quartzy
Selling Your CERo Therapeutics Holdings Inc (CERO) Stock? Here’s What You Need To Know - Stocks Register
Cero Therapeutics holdings sees $325,000 stock sale by YK Bioventures - Investing.com India
FDA clears CERo's new AML drug for phase 1 trials - Investing.com
FDA clears CERo's new AML drug for phase 1 trials By Investing.com - Investing.com UK
CERo Therapeutics, Inc. Receives FDA Clearance of - GlobeNewswire
CERo Therapeutics Secures FDA Clearance for Novel AML Treatment Clinical Trial | CERO Stock News - StockTitan
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Nuclear stock Oklo jumps on data center partnership - Investing.com
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
CERo Therapeutics’ (CERO) Stock Sees Significant Climb After Revealing Ovarian Cancer Data - TipRanks
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
CERo Therapeutics Holdings, Inc. (CERO): 173% Stock Surge Driven by Promising Preclinical Data for Lead Compound CER-1236 - BP Journal
Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga
Nasdaq Moves Lower; Canaan Shares Surge - Benzinga
U.S. Stock market: Binah Capital Group(+105.01%) and CERo Therapeutics(+152.00%) see strong gains, RAPT Therapeutics(−44.12%) declines during mid day trading - Business Upturn
U.S. Stock market: RAPT Therapeutics drops 41% while CERo Therapeutics surges 136% in early trading - Business Upturn
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results - Benzinga
CERo Therapeutics, Inc. Presents Preclinical Data - GlobeNewswire
CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan
Decisive Dividend Corp (DE-X) QuotePress Release - The Globe and Mail
Cero Therapeutics faces NASDAQ delisting - Investing.com India
Cero Therapeutics faces NASDAQ delisting By Investing.com - Investing.com UK
Cero Therapeutics Faces NASDAQ Delisting Over Low Stock Price - Investing.com India
CERo Therapeutics updates on clinical hold and management changes - Investing.com India
CERo Therapeutics updates on clinical hold and management changes By Investing.com - Investing.com South Africa
CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter - Marketscreener.com
CERo Therapeutics, Inc. Provides Corporate Update - The Bakersfield Californian
CERO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Are Investors Inclined To Sell Their CERo Therapeutics Holdings Inc. (NASDAQ: CERO) Holdings? - Stocks Register
A closer look at CERO’s price-to-free cash flow ratio - US Post News
CERo Therapeutics Holdings Inc.’s Market Journey: Closing Strong at 0.10, Up 0.63 - The Dwinnex
Take off with CERo Therapeutics Holdings Inc. (CERO): Get ready for trading - SETE News
Cero Therapeutics announces financial update and board changes - Investing.com India
Cero Therapeutics announces financial update and board changes By Investing.com - Investing.com South Africa
Cero Therapeutics Holdings Inc Stock (CERO) Financials Data
There is no financial data for Cero Therapeutics Holdings Inc (CERO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Cero Therapeutics Holdings Inc Stock (CERO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
| SLOAN STUART M | 10% Owner |
Sep 25 '24 |
Sale |
0.10 |
532,486 |
55,538 |
21,067,956 |
| YK Bioventures Opportunities G | 10% Owner |
Oct 10 '24 |
Sale |
0.10 |
3,250,000 |
325,000 |
22,620,783 |
0.10%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):